

TARO PHARMACEUTICAL INDUSTRIES LTD.

BALANCE SHEETS

	March 31, 2024	March 31, 2023
	U.S. Dollars	
	Unaudited	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	17,774,798	6,649,672
Short-term bank deposits	19,000,000	38,000,000
Current maturities of LT Bank Deposits	-	-
Restricted short term bank deposit	-	-
Marketable Securities	66,387,365	72,712,275
Trade accounts receivable	7,824,688	4,564,976
Other receivables and prepaid expenses:		
Prepaid expenses	4,096,679	3,453,116
Deferred income taxes	-	-
Government authorities	1,819,595	2,942,844
Advances to suppliers	435,390	366,698
Derivative instruments	59,927	6,653
Intercompany balances	22,898,575	15,027,459
Other	2,004,149	1,313,930
TOTAL Other receivables and prepaid expenses	31,314,315	23,110,700
Inventories	70,771,613	70,648,047
TOTAL CURRENT ASSETS	213,072,779	215,685,670
Long Term Receivables and Other Assets	1,485,920,877	1,423,047,890
Long Term Marketable Securities	74,743,780	63,230,361
	1,560,664,657	1,486,278,251
ROU Assets, net	1,547,860	665,487
FIXED ASSETS:		
Cost	323,571,393	310,248,858
Less - accumulated depreciation	(224,785,276)	(212,337,262)
	98,786,117	97,911,596
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	-	-
DEFERRED INCOME TAXES	-	-
TOTAL ASSETS	\$ 1,874,071,413	\$ 1,800,541,004

TARO PHARMACEUTICAL INDUSTRIES LTD.

BALANCE SHEETS

	March 31, 2024	March 31, 2023
	U.S. Dollars	
	Unaudited	
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Short-term bank credit	\$ -	\$ -
Current maturities of long-term debt	-	-
Accounts payable:		
Trade payables	11,833,641	15,755,161
Other current liabilities:		
Returns reserve	194,953	231,788
Due to customers	444,244	358,699
Intercompany balances	-	-
Lease Liability	1,263,840	700,991
Employees and payroll accruals	13,454,096	10,552,721
Current Maturities of Long Term Incentive Plan (LTIP)	270,000	-
Deferred revenue	348,070	85,000
Accrued income taxes	35,113,440	28,255,129
Legal and audit fees	678,787	732,472
Settlements and loss contingencies	2,625,500	2,120,000
Accrued expenses	7,884,082	4,553,028
Interest payable	-	-
Derivative instruments	1,318,383	3,547,727
Deferred taxes	-	-
Suppliers of property, plant and equipment	1,209,226	763,426
Payable on Purchase of treasury stock	-	-
Payable on Purchase of Marketable Securities	245,098	-
Other	(159,936)	(115,666)
TOTAL Other current liabilities	64,889,783	51,785,315
TOTAL CURRENT LIABILITIES	76,723,424	67,540,476
LONG-TERM LIABILITIES:		
Long-term debt, net of current maturities	-	-
Deferred income taxes	-	-
Derivative instruments	-	461,156
Other long-term liabilities	2,148,725	1,681,615
	2,148,725	2,142,771
SHAREHOLDERS' EQUITY	1,795,199,264	1,730,857,757
	\$ 1,874,071,413	\$ 1,800,541,004

Date of approval of the  
financial statements

William Coote  
VP, Chief Financial Officer

TARO PHARMACEUTICAL INDUSTRIES LTD.

STATEMENTS OF INCOME

	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023
	U.S. Dollars	
	Unaudited	
Sales	\$ 190,060,793	\$ 144,143,803
Cost of sales	136,958,117	129,302,491
Gross profit	53,102,676	14,841,312
Research and development	34,125,562	31,350,247
Selling and marketing expenses	8,989,903	10,360,471
Settlements and loss contingencies	-	-
General and administrative expenses	20,796,229	15,514,821
Operating income	(10,809,018)	(42,384,227)
Financing income, net	7,862,607	6,811,079
Other income	2,205,492	382,193
Income before taxes on income	(740,919)	(35,190,955)
Taxes on income	1,946,682	1,300,732
Discontinued operation		
Net income for the period before subsidiaries and dividend	(2,687,601)	(36,491,687)
Dividend income, net	-	-
Subsidiaries	58,748,878	61,936,663
Net income for the period	\$ 56,061,277	\$ 25,444,976

**TARO PHARMACEUTICAL INDUSTRIES LTD.**

**Changes in Shareholders' Equity**

	Share Capital	Additional paid in capital	Accumulated other comprehensive loss	Treasury stock	Dividend	Retained Earnings	Total Shareholders' Equity
<b>U.S. Dollars</b>							
<b>Un-audited</b>							
<b>Balance at March 31, 2021</b>	680,164	262,445,018	(151,620,126)	(746,472,876)	(500,000,000)	2,838,614,281	1,703,646,461
Foreign Currency translation adjustments			(316,131)				(316,131)
Previous years adjustment			(17,027,869)				(17,027,869)
Unrealized losses on available for sale marketble securities				(24,933,513)			(24,933,513)
Treasury stock						(8,191,368)	(8,191,368)
Net income						58,266,105	58,266,105
<b>Balance at March 31, 2022</b>	680,164	262,445,018	(168,964,126)	(771,406,389)	(500,000,000)	2,888,689,018	1,711,443,685
Foreign Currency translation adjustments			(5,101,353)				(5,101,353)
Unrealized losses on available for sale marketble securities			(924,606)				(924,606)
Re-measurements of defined benefits plans (IAS-19)			(4,947)				(4,947)
Treasury stock				-			-
Retained Earnings adjustment						-	-
Net income						25,444,976	25,444,976
<b>Balance at March 31, 2023</b>	680,164	262,445,018	(174,995,032)	(771,406,389)	(500,000,000)	2,914,133,994	1,730,857,755
Foreign Currency translation adjustments			1,926,146				1,926,146
Unrealized losses on available for sale marketble securities			6,354,089				6,354,089
Re-measurements of defined benefits plans (IAS-19)			4,947				4,947
Treasury stock				-			-
Retained Earnings adjustment						-	-
Net income						56,056,326	56,056,326
<b>Balance at March 31, 2024</b>	680,164	262,445,018	(166,709,850)	(771,406,389)	(500,000,000)	2,970,190,320	1,795,199,263